Gene Security Network, provider of a test used to screen chromosomes in in-vitro fertilization processes, has brought in $6 million in second-round funding to grow its sales and marketing operations. The investment, paired with grants received from the National Institutes of Health, will give the Redwood City, Calif. company a two-year runway, it says.
The test, already being sold, detects chromosomal abnormalities that might lead to Down Syndrome and other conditions. It's currently being offered at select in-vitro fertilization clinics across the country.
Claremont Creek Ventures led the round, which also included Sequoia Capital and Alafi Capital. Gene Security Network has raised $10 million to date.